GLPwatch
GLP-1RAs for peripheral artery disease: A remarkable STRIDE in the right direction.
Cell Metab · 2025
Last updated 2026-05-28In a trial called STRIDE, the GLP-1 drug semaglutide improved walking ability and blood flow in people with type 2 diabetes who also had peripheral artery disease (PAD). The study found that semaglutide slowed the worsening of PAD in these patients.
AI summary of the abstract below.
| Journal | Cell Metab, 2025 |
|---|---|
| Citations | 3 |
| Molecules | — |
| Conditions studied | Cardiovascular Risk Reduction |
Abstract
With the rising prevalence of T2D worldwide, peripheral artery disease (PAD) now affects >230 million individuals globally. In the recent STRIDE trial, Bonaca et al. demonstrated that semaglutide improved walking capacity and hemodynamic parameters and slowed PAD progression in patients with T2D. These results reveal an unanticipated vasculoprotective benefit of GLP-1RAs.
Verbatim abstract via PubMed 40466625 ↗